Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Trillium Therapeutic (TRIL)

Trillium Therapeutic (TRIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Trillium Therapeutic 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 CAN

trilliumtherapeutics.com P: 416-595-0627

Description:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (`do not eat`) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (`eat`) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties.

Key Statistics

Overview:

Market Capitalization, $K 1,936,108
Shares Outstanding, K 104,995
Annual Sales, $ 150 K
Annual Net Income, $ -59,350 K
Last Quarter Sales, $ 10 K
Last Quarter Net Income, $ -18,400 K
60-Month Beta 2.08
% of Insider Shareholders 9.10%
% of Institutional Shareholders 87.15%
Float, K 95,440
% Float 90.90%

Growth:

1-Year Return 22.12%
3-Year Return 556.23%
5-Year Return 122.17%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 57.83%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/15/21
Earnings Per Share ttm -0.61
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -157.14%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 11/20/14

TRIL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -27.27%
Return-on-Assets % -23.97%
Profit Margin % -39,566.66%
Debt/Equity 0.00
Price/Sales 12,748.38
Price/Cash Flow N/A
Price/Book 8.50
Book Value/Share 2.48
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar